Literature DB >> 34916684

[Analysis of clinical characteristics of Henoch-Schonlein purpura patients from different altitudes in plateau areas].

H Wei1, Z Luo2.   

Abstract

OBJECTIVE: To investigate the clinical characteristics of Henoch-Schonlein purpura (HSP) patients from different altitudes in Tibet plateau areas of China.
METHODS: A retrospective study was used to analyze the 190 HSP patients admitted to Tibet Autonomous Region People ' s Hospital form April 2014 to May 2021. The subjects were divided into 3 groups according to the altitude of long-term residence before onset and the clinical data at different altitudes were compared and analyzed.
RESULTS: There were no significant differences in the age of onset and gender in HSP patients at different altitudes (P>0.05). The HSP patients in high altitude areas were more likely to have digestive symptoms (P < 0.01). The patients were more likely to have kidney or joint involvement at higher altitudes. The platelets [(512.1±55.0)×109 /L] and C reactive protein [11.2 (5.7, 19.4) g/L] in high altitude areas were significantly higher than at medium altitudes [(498.3±76.9)×109 /L and 9.5 (4.6, 13.5) g/L] and lower altitudes [(456.4±81.2)×109/L and 3.7 (0.2, 8.9) g/L] respectively. The effective rate of treatment was 98.9%, while there was no significant difference of outcome from different altitudes (P>0.05). The patients who were repeatedly hospitalized all had kidney involvement and no immunosuppressive agents were added in the initial treatment.
CONCLUSION: HSP is common in high altitude areas. There was little difference in age of onset and gender at different altitudes. Abdominal pain was the most common clinical manifestation. Patients in high altitude areas were more likely to have severe abdominal problems. Kidney involvement may be poor prognostic factor. Early application of glucocorticoid combined with immunosuppressive agents can effectively control the disease and reduce the recurrence of HSP.

Entities:  

Keywords:  Abdominal manifestations; Clinical characteristics; Henoch-Schonlein purpura (HSP); High altitude area

Mesh:

Year:  2021        PMID: 34916684      PMCID: PMC8695144     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  19 in total

1.  Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins.

Authors:  Janet M M Gardner-Medwin; Pavla Dolezalova; Carole Cummins; Taunton R Southwood
Journal:  Lancet       Date:  2002-10-19       Impact factor: 79.321

2.  Henoch-Schönlein nephritis with nephrotic state in children: predictors of poor outcomes.

Authors:  Hitoshi Wakaki; Kenji Ishikura
Journal:  Pediatr Nephrol       Date:  2011-11-15       Impact factor: 3.714

3.  Cutaneous vasculitis in ulcerative colitis mimicking Henoch-Schönlein purpura.

Authors:  Guilherme Trudes de Oliveira; Sofia Simão Martins; Mariana Deboni; Patrícia Picciarelli; Lúcia Maria Arruda Campos; Adriana Almeida Jesus; Yu Kar Ling Koda; Clovis Artur Silva
Journal:  J Crohns Colitis       Date:  2012-05-22       Impact factor: 9.071

4.  The clinical spectrum of Henoch-Schönlein purpura in children: a single-center study.

Authors:  Şerife Gül Karadağ; Ayşe Tanatar; Hafize Emine Sönmez; Figen Çakmak; Aysel Kıyak; Sevgi Yavuz; Mustafa Çakan; Nuray Aktay Ayaz
Journal:  Clin Rheumatol       Date:  2019-02-08       Impact factor: 2.980

Review 5.  IgA vasculitis (Henoch-Shönlein purpura) in adults: Diagnostic and therapeutic aspects.

Authors:  Alexandra Audemard-Verger; Evangeline Pillebout; Loïc Guillevin; Eric Thervet; Benjamin Terrier
Journal:  Autoimmun Rev       Date:  2015-02-14       Impact factor: 9.754

6.  Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial.

Authors:  Jaana Ronkainen; Olli Koskimies; Marja Ala-Houhala; Marjatta Antikainen; Jussi Merenmies; Jukka Rajantie; Timo Ormälä; Juha Turtinen; Matti Nuutinen
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

7.  [Clinical analysis of childhood Henoch-Schonlein purpura on the Tibetan Plateau, China].

Authors:  Zhen Yang; Lin Guo; Hao Xiong; Zhu Gang; Jian-Xin Li; Yu-Ping Deng; Qu-Zhen Dawa; Zha-Xi Pubu; Hui Li
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2014-12

Review 8.  Henoch-Schönlein purpura nephritis in children: risk factors, prevention and treatment.

Authors:  Radovan Bogdanović
Journal:  Acta Paediatr       Date:  2009-07-24       Impact factor: 2.299

9.  High-dose methylprednisolone pulse therapy for treatment of refractory intestinal involvement caused by Henoch-Schönlein purpura: a case report.

Authors:  Hyun Sik Kang; Hee Sup Chung; Ki-Soo Kang; Kyoung Hee Han
Journal:  J Med Case Rep       Date:  2015-03-24

10.  Clinical and Pathological Characteristics of Elderly Japanese Patients with IgA Vasculitis with Nephritis: A Case Series.

Authors:  Hiroyuki Ueda; Yoichi Miyazaki; Nobuo Tsuboi; Keita Hirano; Shinya Yokote; Emi Kobayashi; Makoto Ogura; Tetsuya Kawamura; Munekazu Ryuzaki; Takashi Yokoo
Journal:  Intern Med       Date:  2018-08-10       Impact factor: 1.271

View more
  1 in total

1.  Development and validation of a nomogram to predict recurrence in children with Henoch-Schönlein purpura.

Authors:  Danyang Song; Yajing Jiang; Qiuju Zhao; Jinling Li
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.